{"entity":{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","aka":["Zhejiang Tongyuankang Pharmaceutical","同源康医药"],"tldr":"TYK Medicines is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the EGFR inhibitor asandeutertinib (TY-9591) and TYK-00540 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and brain and spinal cord tumours.","summary":"TYK Medicines (Zhejiang Tongyuankang) is a Chinese biotechnology company listed in Hong Kong that discovers, develops and manufactures small-molecule targeted cancer drugs, with research centres in Changxing and Zhengzhou. Its EGFR inhibitor asandeutertinib (TY-9591) has been approved in China for EGFR-mutant lung cancer with brain metastases. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo (1 in phase 3 or 2/3): FLETEO (phase 3, Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Ce...), NCT06950086 (phase 1/2, Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors) and NCT05948813 (phase 2, TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.tykmedicines.com"},{"label":"ClinicalTrials.gov: trials led by TYK Medicines","url":"https://clinicaltrials.gov/search?lead=TYK%20Medicines%2C%20Inc"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","breast-hr-positive","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["ty-9591","osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["fleteo","nct06950086","nct05948813"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.tykmedicines.com","ticker":"HKEX:2410","founded":2017,"stage":"public","investors":[],"funding":[]},"route":"/companies/tyk-medicines/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"ty-9591","kind":"drug","name":"TY-9591","route":"/drugs/ty-9591/"}],"trial":[{"id":"fleteo","kind":"trial","name":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","route":"/trials/fleteo/"},{"id":"nct06950086","kind":"trial","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06950086/"},{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/"}]}}